Author:
Geyer Julia T.,Orazi Attilio
Publisher
Springer International Publishing
Reference7 articles.
1. Bacher, U., Haferlach, T., Schnittger, S., et al. (2011). Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. British Journal of Haematology, 153, 149–167.
2. Itzykson, R., Kosmider, O., Renneville, A., et al. (2013). Prognostic score including gene mutations in chronic myelomonocytic leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 2428–2436.
3. Kohlmann, A., Grossmann, V., Klein, H. U., et al. (2010). Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 3858–3865.
4. Kosmider, O., Gelsi-Boyer, V., Ciudad, M., et al. (2009). TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica, 94, 1676–1681.
5. Orazi, A., Bennett, J. M., Germing, U., Brunning, R. D., Bain, B. J., Cazzola, M., Foucar, K., Thiele, J., Baumann, I., Niemeyer, C. M., Hasserhian, R. P., & Malcovati, L. (2017). Myelodysplastic/myeloproliferative neoplasms. Lyon: IARC.